See more : Regions Financial Corporation (RN70.F) Income Statement Analysis – Financial Results
Complete financial analysis of Intensity Therapeutics, Inc. (INTS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Intensity Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Eshallgo Inc. Class A Ordinary Shares (EHGO) Income Statement Analysis – Financial Results
- Earth Alive Clean Technologies Inc. (EACTF) Income Statement Analysis – Financial Results
- Rigel Pharmaceuticals, Inc. (RIGL) Income Statement Analysis – Financial Results
- Phoenix Footwear Group, Inc. (PXFG) Income Statement Analysis – Financial Results
- BGF retail CO., LTD. (282330.KS) Income Statement Analysis – Financial Results
Intensity Therapeutics, Inc. (INTS)
About Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 147.00K | 179.04K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -147.00K | -179.04K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 4.79M | 5.13M | 5.86M | 5.05M | 4.44M |
| General & Administrative | 3.53M | 2.42M | 2.16M | 1.17M | 1.24M |
| Selling & Marketing | -147.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.39M | 2.42M | 2.16M | 1.17M | 1.24M |
| Other Expenses | 0.00 | 47.65K | 115.51K | 118.76K | 144.99K |
| Operating Expenses | 8.17M | 7.55M | 8.01M | 6.22M | 5.68M |
| Cost & Expenses | 8.32M | 7.55M | 8.01M | 6.22M | 5.68M |
| Interest Income | 324.00K | 2.48K | 2.61K | 74.01K | 150.71K |
| Interest Expense | 305.00K | 81.78K | 16.77K | 0.00 | 0.00 |
| Depreciation & Amortization | 147.00K | 179.04K | 236.56K | 206.30K | 171.86K |
| EBITDA | -10.09M | -7.40M | -7.88M | -6.03M | -5.38M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.32M | -7.63M | -8.01M | -6.22M | -5.68M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.22M | 49.06K | 118.12K | 192.77K | 295.70K |
| Income Before Tax | -10.54M | -7.58M | -7.90M | -6.03M | -5.38M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -131.91K | -2.61K | -74.01K | -150.71K |
| Net Income | -10.54M | -7.45M | -7.89M | -5.96M | -5.23M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.38 | -0.57 | -0.60 | -0.45 | -0.40 |
| EPS Diluted | -1.38 | -0.57 | -0.60 | -0.45 | -0.40 |
| Weighted Avg Shares Out | 8.62M | 13.10M | 13.10M | 13.10M | 13.10M |
| Weighted Avg Shares Out (Dil) | 8.62M | 13.10M | 13.10M | 13.10M | 13.10M |
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate
Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024
Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024
Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference
Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program
Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer
Why Is Intensity Therapeutics (INTS) Stock Up 133% Today?
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS
Source: https://incomestatements.info
Category: Stock Reports